Evaluation of Toxicities With Thoracic Radiation Therapy and Immune Checkpoint Inhibition in Non-small Cell Lung Cancer
The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiation therapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society
